Researchers have developed the Huntington’s Disease Manifest Quality of Life (HD-mQoL) measure, the first tool specifically designed to capture the needs-based patient experience for those living with Huntington’s disease. Published in the Journal of Neurology by Isobel Spray and colleagues at Galen Research, the 23-item instrument provides a validated framework for assessing treatment outcomes in clinical trials and real-world practice.
Why is a new quality of life measure needed for Huntington’s disease?
Current patient-reported outcome measures often fail to account for the specific, day-to-day burdens faced by individuals with Huntington’s disease (HD). According to the study by Spray et al., existing tools do not adequately capture the “lived experience” of patients, which is critical since no curative treatments currently exist for the hereditary neurodegenerative disorder. By focusing on needs-based metrics, the HD-mQoL aims to provide a more accurate assessment of how new therapies affect a patient’s actual quality of life rather than just measuring motor or cognitive symptoms.
The HD-mQoL validation process included participants from the United Kingdom, Ireland, the Czech Republic, Germany, Italy, and the Netherlands to ensure the measure remains relevant across different cultural backgrounds.
How was the HD-mQoL measure validated?
The development process spanned three distinct stages to ensure both scientific rigor and clinical relevance. Initially, researchers conducted qualitative interviews across multiple European countries to generate content. Following this, cognitive debriefing interviews with patients helped refine the specific items and instructions. The final stage involved a validation survey completed by 238 participants, followed by a second survey of 181 participants two weeks later to establish test-retest reliability.
Statistical performance of the new measure
The final 23-item tool demonstrated strong psychometric properties, according to data analyzed using Rasch Measurement Theory and Classical Test Theory. The study reports:
- Reliability: Excellent internal consistency with a Cronbach’s α of 0.91 at the first timepoint and 0.92 at the second.
- Stability: A test-retest reliability score of r=0.87.
- Model Fit: An item–trait interaction χ2 of 0.391.
What does this mean for future HD clinical trials?
The HD-mQoL is designed to be a robust tool for international clinical trials, offering a way to differentiate between patient subgroups based on self-rated disease severity and general health. By minimizing floor and ceiling effects, the measure allows researchers to track smaller, meaningful changes in a patient’s life over time. This standardization could lead to more consistent data collection across global research sites, making it easier for regulators to evaluate the true value of emerging Huntington’s therapies.
When assessing new treatments for neurodegenerative conditions, look for clinical trials that prioritize patient-reported outcomes (PROs) alongside traditional biomarkers to get a complete picture of therapeutic success.
Frequently Asked Questions
- What is the primary purpose of the HD-mQoL?
- It is a needs-based, patient-reported outcome measure designed to quantify the quality of life for people living with Huntington’s disease.
- How many items are in the final HD-mQoL tool?
- The final version consists of 23 items, reduced from an initial pool of 49 during the validation process.
- Is the HD-mQoL suitable for use outside the UK?
- Yes, the researchers developed the tool with international use in mind, incorporating qualitative data from Germany, Italy, the Netherlands, and the Czech Republic.
Are you interested in how patient-reported outcomes are changing the landscape of neurodegenerative research? Subscribe to our monthly research newsletter to stay updated on the latest clinical developments and validation studies.
Related reading
